As shown previously in the preclinical and clinical studies by us and others, most solid tumors rarely depend only on BCL-xL for survival and thus respond poorly to the single agent treatment that targets BCL-xL alone except cutaneous T cell lymphoma (CTCL) [5, 7–10]. The gene discussed is BCL2L1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.